Treatment Use Study for Advanced Melanoma.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00584493|
Recruitment Status : No longer available
First Posted : January 2, 2008
Last Update Posted : December 14, 2009
|Condition or disease||Intervention/treatment|
|Advanced Unresectable Melanoma||Drug: CP-675,206|
|Study Type :||Expanded Access|
|Official Title:||Treatment Use Study of CP-675,206 for Advanced Melanoma|
|Study Start Date :||May 2008|
This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma
Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00584493
|Study Director:||Pfizer CT.gov Call Center||Pfizer|